Related Experiment Video
Updated: Jun 17, 2026
09:15
Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Moderate Intensity Statins Plus Ezetimibe Combination Therapy Versus High Intensity Statins Monotherapy After
Emad Uddin Sajid1, Muhammad Hasnain Azeem1, Alishba Fatima1
1Department of Medicine, Dow University of Health Sciences, Karachi, Pakistan.
Clinical Cardiology
|June 15, 2026
Summary
Moderate-intensity statin plus ezetimibe may offer similar cardiovascular outcomes to high-intensity statins after percutaneous coronary intervention (PCI). Further large randomized trials are needed to confirm long-term efficacy and safety for acute coronary syndrome (ACS) patients.
Area of Science:
- Cardiology
- Pharmacology
- Clinical Research
Background:
- High-intensity statins are standard post-percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS).
- Tolerability issues and residual cardiovascular risk with high-intensity statins present challenges.
- Moderate-intensity statin plus ezetimibe is a potential alternative, but its comparative effectiveness is uncertain.
Purpose of the Study:
- To compare the effectiveness of moderate-intensity statin plus ezetimibe versus high-intensity statin therapy after PCI.
- To evaluate major adverse cardiovascular events (MACE) and secondary endpoints.
Main Methods:
- Systematic review and meta-analysis following PRISMA guidelines.
- Searched PubMed, Cochrane Library, and ClinicalTrials.gov through September 2025.
- Included 9 studies with 179,621 patients comparing the two treatment strategies.
Main Results:
- No significant difference in MACE (RR 0.96, 95% CI 0.81-1.12).
- Modest, non-robust reductions in cardiovascular mortality (RR 0.83) and myocardial infarction (MI) (RR 0.74).
- Similar revascularization rates; lower heterogeneity in intermediate follow-up and non-ACS populations.
Conclusions:
- Moderate-intensity statin plus ezetimibe may offer comparable cardiovascular outcomes to high-intensity statins post-PCI.
- Persistent heterogeneity limits certainty regarding efficacy.
- Large randomized trials are necessary to confirm long-term safety and effectiveness.
Related Concept Videos
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:28Acute Coronary Syndrome IV: Interprofessional Care
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:27Peripheral Artery Disease III: Interprofessional Care
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...